Special Issue

Novel Delivery Systems and Approaches for Antibiotics: Recent Advances and Future Directions

Message from the Guest Editors

Antibiotics, alongside vaccines, are one of medicine's greatest interventions, having revolutionized the treatment of serious bacterial infections. However, antibiotic use is not without repercussions, inducing negative effects on the host. Moreover, the increasingly frequent acquisition of multidrug-resistant strains has threatened the usefulness of the currently available antibiotics. Added to this threat is the limited discovery and development of novel antimicrobials. To tackle this problem, researchers have begun to utilize advanced pharmaceutical formulation as a means to develop novel delivery systems for the enhanced delivery and therapeutic efficacy of antibiotics, while concomitantly mitigating the negative effects induced to the host. In this context, we encourage and appreciate the presentation of this Special Issue. These articles will encapsulate the current dynamism of this field, focusing on recent advancements in the development and evaluation of novel delivery approaches for antibiotics. Contributions addressing novel approaches to minimizing the negative effects of antibiotics in the host will also be appreciated.

Guest Editors

Dr. Aoife M Rodgers

Department of Biology, Maynooth University, Maynooth, Co. Kildare, Ireland

Dr. Aaron J. Courtenay

School of Pharmacy and Pharmaceutical Sciences, Ulster University, Cromore Road, Londonderry BT52 1SA, UK

Deadline for manuscript submissions

closed (31 May 2024)



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/139073

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

